(May 22, 2018, 10:40 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on May 21 denied review of a case by two whistleblowers who claimed that the former Solvay Pharmaceuticals engaged in off-label marketing of three drugs, including AndroGel, and caused the submission of false claims to federal health care programs (United States, ex rel. John King, et al. v. Solvay Pharmaceuticals, Incorporated, No. 17-1370, U.S. Sup.)....